Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-01-29 9:33 pm Purchase | 2026-01-22 | 13G | NextCure, Inc. NXTC | Affinity Asset Advisors LLC | 348,607 9.990% | 156,725 (+81.68%) | Filing History |
| 2026-01-29 9:32 pm Purchase | 2026-01-22 | 13G | Karyopharm Therapeutics Inc. KPTI | Affinity Asset Advisors LLC | 1,713,092 8.600% | 1,048,868 (+157.91%) | Filing History |
| 2026-01-29 9:29 pm Purchase | 2026-01-22 | 13G | iBio, Inc. IBIO | Affinity Asset Advisors LLC | 2,401,616 9.990% | 220,196 (+10.09%) | Filing History |
| 2026-01-29 7:59 pm Purchase | 2026-01-22 | 13G | Ventyx Biosciences, Inc. VTYX | Affinity Asset Advisors LLC | 6,465,041 9.000% | 2,407,936 (+59.35%) | Filing History |
| 2026-01-29 7:59 pm Unchanged | 2026-01-22 | 13G | Verrica Pharmaceuticals Inc. VRCA | Affinity Asset Advisors LLC | 884,172 5.500% | 0 (Unchanged) | Filing History |
| 2026-01-29 7:58 pm Purchase | 2026-01-22 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Affinity Asset Advisors LLC | 5,217,660 7.100% | 965,655 (+22.71%) | Filing History |
| 2026-01-29 7:58 pm Purchase | 2026-01-22 | 13G | Sutro Biopharma, Inc. STRO | Affinity Asset Advisors LLC | 748,382 8.800% | 748,382 (New Position) | Filing History |
| 2026-01-29 7:57 pm Sale | 2026-01-22 | 13G | Forte Biosciences, Inc. FBRX | Affinity Asset Advisors LLC | 834,964 6.700% | -27,436 (-3.18%) | Filing History |
| 2026-01-29 7:57 pm Unchanged | 2026-01-22 | 13G | Ovid Therapeutics Inc. OVID | Affinity Asset Advisors LLC | 12,149,166 9.000% | 0 (Unchanged) | Filing History |
| 2026-01-29 7:56 pm Purchase | 2026-01-22 | 13G | Avalo Therapeutics, Inc. AVTX | Affinity Asset Advisors LLC | 1,051,054 5.700% | 44,837 (+4.46%) | Filing History |
| 2025-12-23 5:15 pm Purchase | 2025-12-17 | 13G | Forte Biosciences, Inc. FBRX | Affinity Asset Advisors LLC | 862,400 6.900% | 862,400 (New Position) | Filing History |
| 2025-12-18 4:06 pm Purchase | 2025-12-11 | 13G | Ovid Therapeutics Inc. OVID | Affinity Asset Advisors LLC | 12,149,166 9.000% | 12,149,166 (New Position) | Filing History |
| 2025-12-03 3:20 pm Purchase | 2025-11-25 | 13G | Verrica Pharmaceuticals Inc. VRCA | Affinity Asset Advisors LLC | 884,172 5.470% | 884,172 (New Position) | Filing History |
| 2025-12-03 3:19 pm Sale | 2025-08-19 | 13G | iBio, Inc. IBIO | Affinity Asset Advisors LLC | 2,181,420 9.990% | -2,098,580 (-49.03%) | Filing History |
| 2025-11-14 4:10 pm Purchase | 2025-09-30 | 13G | NextCure, Inc. NXTC | Affinity Asset Advisors LLC | 191,882 7.170% | 191,882 (New Position) | Filing History |
| 2025-11-13 5:21 pm Purchase | 2025-09-30 | 13G | Avalo Therapeutics, Inc. AVTX | Affinity Asset Advisors LLC | 1,006,217 7.650% | 455,452 (+82.69%) | Filing History |
| 2025-10-23 4:07 pm Purchase | 2025-10-16 | 13G | Sutro Biopharma, Inc. STRO | Affinity Asset Advisors LLC | 658,377 7.770% | 658,377 (New Position) | Filing History |
| 2025-08-26 4:47 pm Purchase | 2025-08-19 | 13G | iBio, Inc. IBIO | Affinity Asset Advisors LLC | 4,280,000 9.990% | 4,280,000 (New Position) | Filing History |
| 2025-06-04 4:04 pm Purchase | 2025-05-28 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | Affinity Asset Advisors LLC | 4,252,005 7.750% | 4,252,005 (New Position) | Filing History |
| 2025-05-30 7:01 pm Purchase | 2025-05-22 | 13G | Ventyx Biosciences, Inc. VTYX | Affinity Asset Advisors LLC | 4,057,105 5.700% | 4,057,105 (New Position) | Filing History |